MedTrace Logo

The Analgesic Efficacy and Safety of Desvenlafaxine in Patients With Herpes Zoster

NCT07361809 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2026-01-23

No results posted yet for this study

Summary

Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Recent attention has focused on the potential role of antidepressants, which have central antinociceptive property and may offer analgesic benefits by modulating central nervous system pain pathways through increased serotonin and norepinephrine availability. Therefore, investigators hypothesize that desvenlafaxine may effectively reduce the severity of HZ pain without significantly increasing adverse events.

Conditions

  • Herpes Zoster
  • Pain

Interventions

DRUG

Desvenlafaxine combined conventional therapy

In the desvenlafaxine combined conventional therapy group, venlafaxine will be initiated at 50 mg daily. The maximum recommended dose is 400 mg daily. In addition, the group will contain conventional treatment for HZ, except desvenlafaxine, including NSAIDs, opioids, antiviral drugs and so on.

DRUG

Conventional therapy

In the conventional therapy group, treatments will include NSAIDs, opioids, antiviral drugs and so on.

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-15
Primary Completion
2027-09-30
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07361809 on ClinicalTrials.gov